Sabine Tejpar
#158,573
Most Influential Person Now
Researcher
Sabine Tejpar's AcademicInfluence.com Rankings
Sabine Tejparlaw Degrees
Law
#2750
World Rank
#3418
Historical Rank
Common Law
#142
World Rank
#154
Historical Rank
Sabine Tejparphilosophy Degrees
Philosophy
#9050
World Rank
#12547
Historical Rank
Logic
#6052
World Rank
#7532
Historical Rank
Sabine Tejparbiology Degrees
Biology
#12379
World Rank
#15850
Historical Rank
Computational Biology
#272
World Rank
#273
Historical Rank
Download Badge
Law Philosophy Biology
Why Is Sabine Tejpar Influential?
(Suggest an Edit or Addition)Sabine Tejpar's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Consensus Molecular Subtypes of Colorectal Cancer (2015) (3194)
- Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. (2009) (2856)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) (1968)
- Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (2011) (1721)
- Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. (2010) (1067)
- KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (2008) (873)
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010) (714)
- Peutz–Jeghers syndrome: a systematic review and recommendations for management (2010) (662)
- Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts (2013) (656)
- A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4) (2004) (653)
- Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (646)
- Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (2017) (637)
- Guidelines for the clinical management of familial adenomatous polyposis (FAP) (2008) (635)
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. (2011) (533)
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017) (532)
- Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. (2014) (465)
- KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience (2008) (418)
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC (2009) (403)
- Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. (2015) (399)
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer (2013) (358)
- Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. (2009) (345)
- Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor) (1999) (343)
- Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. (2007) (339)
- Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. (2012) (330)
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer (2009) (304)
- Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. (2015) (285)
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program (2008) (234)
- Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. (2012) (225)
- Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer (2020) (225)
- Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. (2007) (218)
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (216)
- Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. (2012) (205)
- A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling (2020) (204)
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer (2017) (204)
- Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. (2016) (196)
- Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages (2020) (189)
- Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes (2017) (185)
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. (2012) (184)
- Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. (2013) (180)
- KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy (2013) (168)
- Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study (2008) (168)
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery (2010) (167)
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program (2008) (140)
- Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). (2019) (137)
- BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression (2016) (137)
- Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. (2015) (132)
- Analysis of genetic and phenotypic heterogeneity in juvenile polyposis (2000) (128)
- Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity (2020) (125)
- Large deletions of the APC gene in 15% of mutation‐negative patients with classical polyposis (FAP): A Belgian study (2005) (123)
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology (2020) (123)
- Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. (2012) (121)
- Recommendations to improve identification of hereditary and familial colorectal cancer in Europe (2010) (121)
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients (2013) (120)
- Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data (2007) (118)
- Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. (2014) (117)
- Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. (2009) (111)
- Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching (2016) (109)
- Targeted therapies: how personal should we go? (2012) (108)
- EGFR-targeted therapy. (2011) (108)
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes (2013) (105)
- Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). (2009) (101)
- Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis (2015) (101)
- The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial (2018) (100)
- Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) (2008) (98)
- IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies (2015) (98)
- Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study (2017) (96)
- External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. (2011) (93)
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells (2013) (93)
- Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy (2014) (88)
- Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. (2017) (86)
- Biopsies: next-generation biospecimens for tailoring therapy (2013) (86)
- Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial (2019) (84)
- Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance (2015) (84)
- A Comprehensive Characterization of Genome-Wide Copy Number Aberrations in Colorectal Cancer Reveals Novel Oncogenes and Patterns of Alterations (2012) (81)
- The ZIC gene family encodes multi-functional proteins essential for patterning and morphogenesis (2013) (81)
- Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. (2009) (81)
- Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. (2016) (76)
- Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers (2015) (75)
- Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. (2020) (75)
- Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). (2009) (75)
- Transcription Factor Zic2 Inhibits Wnt/β-Catenin Protein Signaling (2011) (74)
- A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility (2016) (74)
- Neutrophils suppress tumor‐infiltrating T cells in colon cancer via matrix metalloproteinase‐mediated activation of TGFβ (2019) (74)
- Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer (2013) (74)
- Guideline on the requirements of external quality assessment programs in molecular pathology (2012) (74)
- Erratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (Nature reviews. Cancer (2017) 17 2 (79-92)) (2017) (74)
- Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. (2014) (73)
- Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study (2017) (72)
- Predictive testing for hereditary nonpolyposis colorectal cancer: subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test. (2005) (71)
- Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial (2013) (70)
- Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients (2010) (69)
- miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan (2014) (68)
- Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis (2017) (66)
- New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer (2010) (65)
- Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. (2011) (65)
- TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. (2007) (64)
- Skin toxicities of targeted therapies. (2009) (63)
- Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). (2014) (61)
- A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy (2014) (59)
- VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. (2017) (56)
- Overcoming resistance to antiangiogenic therapies. (2012) (55)
- Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. (2015) (53)
- DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. (2016) (53)
- A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency# (2012) (53)
- Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (2011) (52)
- Invasion and MMP expression profile in desmoid tumours (2004) (51)
- Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. (2014) (51)
- Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial (2010) (51)
- Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling. (2010) (49)
- Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer (2016) (49)
- Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors (2005) (49)
- Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. (2014) (47)
- Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study (2011) (45)
- Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. (2011) (45)
- Analysis of Wnt/Beta catenin signalling in desmoid tumors. (2005) (45)
- The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. (2009) (44)
- Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents (2011) (43)
- Identification of IGFBP-6 as a significantly downregulated gene by β-catenin in desmoid tumors (2004) (43)
- Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells (2012) (42)
- Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series (2008) (42)
- The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). (2011) (41)
- A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling (2020) (41)
- European perspective for effective cancer drug development (2014) (40)
- Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer (2013) (40)
- Tcf-3 expression and β -catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour) (2001) (39)
- CGH arrays compared for DNA isolated from formalin‐fixed, paraffin‐embedded material (2012) (39)
- Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial (2009) (38)
- EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab (2014) (37)
- Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (2017) (37)
- Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. (2016) (36)
- Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas (2019) (35)
- Expression of the E‐cadherin–catenin complex in lung neuroendocrine tumours (2001) (34)
- The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer (2020) (34)
- Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial. (2014) (34)
- Clinical biomarkers in oncology: focus on colorectal cancer. (2009) (33)
- Steps forward for cancer precision medicine (2017) (33)
- AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer (2020) (33)
- ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations (2007) (33)
- Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. (2013) (33)
- Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial (2017) (32)
- Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer (2015) (32)
- Molecular and genetic defects in colorectal tumorigenesis. (2002) (32)
- microRNAs in colon cancer: A roadmap for discovery (2012) (31)
- Familial Adenomatous Polyposis-Associated Desmoids Display Significantly More Genetic Changes than Sporadic Desmoids (2011) (31)
- Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). (2004) (31)
- KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance (2012) (31)
- Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer (2022) (31)
- Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. (2014) (30)
- β-Catenin Overexpression in Dupuytren’s Disease Is Unrelated to Disease Recurrence (2009) (27)
- Zic2 mutation causes holoprosencephaly via disruption of NODAL signalling. (2016) (27)
- The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling (2014) (26)
- Societal challenges of precision medicine: Bringing order to chaos. (2017) (25)
- Clinical Biomarkers in Oncology (2012) (25)
- Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. (2006) (25)
- FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study (2014) (24)
- Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. (2015) (24)
- Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial (2018) (23)
- 6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium (2009) (23)
- Clinical validation of high‐resolution fast spin‐echo MR colonography after colon distention with air (2005) (22)
- Improved postoperative outcome of segmental fasciectomy in Dupuytren disease by insertion of an absorbable cellulose implant (2011) (22)
- Biopsies: next-generation biospecimens for tailoring therapy (2013) (22)
- Zeb2 drives invasive and microbiota-dependent colon carcinoma (2020) (22)
- Immunohistochemical evidence for Zic1 coexpression with β-catenin in the myofibroblast of Dupuytren disease (2009) (21)
- Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD) (2002) (21)
- DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype (2013) (21)
- The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. (2013) (20)
- The use of molecular markers in the diagnosis and treatment of colorectal cancer (2007) (20)
- Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer (2013) (20)
- KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab (2007) (20)
- Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer (2013) (20)
- Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells (2016) (20)
- Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors. (2006) (19)
- Mutant Kras And Braf Gene Expression Profiles In Colorectal Cancer: Results Of The Translational Study On The Petacc 3-Eortc 40993-Sakk 60-00 Trial (2010) (19)
- Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. (2015) (18)
- Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. (2008) (18)
- A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs) (2008) (18)
- Expression of FOXP1 and Colorectal Cancer Prognosis. (2015) (18)
- Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis (2021) (17)
- High Amphiregulin and Epiregulin expression in K-ras wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease (2007) (17)
- The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer (2020) (17)
- High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial. (2014) (17)
- CCR New Strategies Clinical Cancer Research New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer (2010) (16)
- Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. (2006) (16)
- Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. (2013) (16)
- Familial adenomatous polyposis: clinical presentation, detection and surveillance. (2011) (15)
- BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer (2021) (15)
- Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells (2022) (15)
- Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: Lessons from the OPUS trial. (2011) (14)
- Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC) (2012) (14)
- Germline Mutations of the hMLH1 and hMSH2 Mismatch Repair Genes in Belgian Hereditary Nonpolyposis Colon Cancer (HNPCC) Patients (2005) (14)
- RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. (2019) (14)
- The human alphaE-catenin gene CTNNA1: mutational analysis and rare occurrence of a truncated splice variant. (2002) (14)
- ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours (2016) (14)
- LBA-005VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. (2017) (13)
- PD-0024 Phase I/II Study of Folfiri Plus the MEK1/2 Inhibitor Pimasertib (MSC1936369B) as Second-Line Treatment for KRAS Mutated Metastatic Colorectal Cancer (2012) (13)
- Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy (2022) (13)
- Proximal and distal colon tumors as distinct biologic entities with different prognoses. (2013) (13)
- The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri (2008) (13)
- Molecular markers in colon cancer have a stage specific prognostic value. results of the translational study on the petacc 3-eortc 40883-sakk 60-00 trial (2009) (13)
- Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results (2008) (12)
- Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. (2020) (12)
- Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). (2020) (12)
- KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab—Reply (2011) (12)
- A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW. (2020) (12)
- Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer (2021) (12)
- Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. (2018) (12)
- Diet and immunocompetence. (1983) (12)
- The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer. (2007) (12)
- DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer (2015) (11)
- An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. (2011) (11)
- Integrating biomarkers in colorectal cancer trials in the West and China (2015) (11)
- Impact of molecular markers on treatment selection in advanced colorectal cancer. (2009) (11)
- Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia (2022) (11)
- Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. (2011) (11)
- Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. (2005) (11)
- Establishing a Unified COVID-19 “Immunome”: Integrating Coronavirus Pathogenesis and Host Immunopathology (2020) (10)
- Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. (2020) (10)
- Faculty Opinions recommendation of Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. (2013) (10)
- Hereditary and familial colon cancer syndromes (2005) (10)
- Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy (2021) (10)
- Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab. (2009) (9)
- The molecular basis of colorectal cancer. (2001) (9)
- P1.28 Dusp4 Expression as A Marker of Heterogeneous Signaling in Colorectal Cancer Patients (2012) (9)
- Deregulation of ZIC Family Members in Oncogenesis. (2018) (8)
- Su1432 I-SCAN Detects More Polyps in Lynch Syndrome (HNPCC) Patients: A Prospective Controlled Randomized Back-to-Back Study (2012) (8)
- POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis (2016) (8)
- Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer (2020) (8)
- Cetuximab Alone or With Irinotecan for Resistant KRAS‐, NRAS‐, BRAF‐ and PIK3CA‐wild‐type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study (2018) (8)
- A textural feature based tumor therapy response prediction model for longitudinal evaluation with PET imaging (2012) (8)
- Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data (2008) (7)
- Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies. (2012) (7)
- Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy (2021) (7)
- Risk stratification for colorectal cancer and implications for screening. (2005) (7)
- Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor (2016) (7)
- Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform. (2015) (7)
- Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab (2008) (6)
- Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC). (2014) (6)
- Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer (2017) (6)
- Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer (2022) (6)
- DUSPs as markers of MEK/Erk activation in primary colorectal cancer. (2009) (6)
- Personalized medicine in metastatic colorectal cancer treated with anti‐epidermal growth factor receptor agents: A future opportunity? (2014) (6)
- KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? (2015) (5)
- Implications of KRAS mutation status for the treatment of metastatic colorectal cancer (2009) (5)
- Association of a specific innate immune response to DNA damage with DNA repair deficient colorectal cancers. (2016) (5)
- Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data (2016) (5)
- Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer (2012) (5)
- Improved first-line chemotherapy: a better chance for surgery? (2010) (5)
- O-0020OUTCOME ACCORDING TO TUMOR RAS MUTATION STATUS IN CRYSTAL STUDY PATIENTS WITH METASTATIC COLORECTAL CANCER RANDOMIZED TO FOLFIRI WITH OR WITHOUT CETUXIMAB AS FIRST-LINE TREATMENT (2014) (5)
- Therapeutic Potential of Replication-Selective Oncolytic Adenoviruses on Cells from Familial and Sporadic Desmoid Tumors (2008) (5)
- The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab (2008) (5)
- O-0025COLORECTAL CANCER SUBTYPING CONSORTIUM (CRCSC) IDENTIFIES CONSENSUS OF MOLECULAR SUBTYPES (2014) (5)
- Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. (2014) (5)
- Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer: Requirements for Accurate Prognosis Assessment. (2016) (5)
- Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients (2021) (5)
- Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. (2010) (5)
- Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease (2014) (4)
- Validation of two gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method. (2012) (4)
- Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts) (2007) (4)
- Identification and validation of gene expression subtypes in a large set of colorectal cancer samples (2012) (4)
- Pan-cancer detection and typing by mining patterns in large genome-wide cell-free DNA sequencing datasets (2022) (4)
- pathological and clinical features (2014) (4)
- pathological and clinical features (2014) (4)
- Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab (2017) (4)
- Linked Colour imaging for the detection of polyps in patients with Lynch syndrome: a multicentre, parallel randomised controlled trial (2021) (4)
- Feedback activation of HER 3 attenuates response to EGFR inhibitors in colon cancer cells (2016) (4)
- Prostatic biopsy-related rectal bleeding refractory to medical and endoscopic therapy definitively managed by catheter-directed embolotherapy: a case report (2015) (4)
- A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. (2018) (4)
- MSI versus MSS sporadic colorectal cancers: Morphology, inflammation, and angiogenesis revisited (2014) (4)
- Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients. (2017) (4)
- Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer: A retrospective analysis. (2011) (4)
- PIK 3 CAMutations Are Not aMajor Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer (2009) (4)
- Highly Dosed Tamoxifen in Therapy-Resisting Dupuytren’s Disease (2012) (4)
- DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease (2008) (4)
- Fuzzy Statistical Unsupervised Learning Based Total Lesion Metabolic Activity Estimation in Positron Emission Tomography Images (2011) (4)
- Genome Scale Epigenetic Profiling Reveals Five Distinct Subtypes of Colorectal Cancer (2018) (3)
- Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab (2011) (3)
- SYNTHESIS NEXT GENERATION SEQUENCING GENE PANELS FOR TARGETED THERAPY IN ONCOLOGY AND HAEMATO-ONCOLOGY (2015) (3)
- Intratumoral heterogeneity in colorectal cancer: Can histology be used as a guidance for molecular testing? (2017) (3)
- Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (2011) (3)
- Standard treatment for metastatic colorectal cancer (CRC) (2006) (3)
- Prognostic stromal and immune response expression patterns in early-stage colorectal cancer predicted by genes intrinsically expressed by tumor epithelial cells. (2019) (3)
- Identification of a Poor-Prognosis BRAF-Mutant Like Populationof Patients With Colon Cancer. Journal of Clinical Oncology,30(12):12BB-1295, 2012 (2012) (3)
- METASTATIC COLORECTAL CANCER: ANALYSIS OF PREDICTIVE UTILITY IN THE CRYSTAL AND OPUS STUDIES (2012) (3)
- Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data (2012) (3)
- Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer (2015) (3)
- Thymidylate synthase (TS) expression as a prognostic molecular marker in stage II/III colon cancer. (2013) (3)
- Charting the Course for a New Cancer Clinical Research Culture (2015) (3)
- ConcomitantBRAFandPI3K/mTORBlockadeIsRequiredfor Effective Treatment of BRAF V600E Colorectal Cancer (2013) (3)
- Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study (2008) (2)
- 479OConsensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial (2017) (2)
- Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer (2021) (2)
- Expression profiling of tumour budding cells in colorectal cancer suggests an EMT-like phenotype and molecular subtype switching (2016) (2)
- Biomarkers to predict response to anti-EGFR antibodies. (2011) (2)
- BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer (2013) (2)
- SLAC: Statistical total lesion metabolic activity computation by fuzzy unsupervised learning of PET images (2013) (2)
- New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC). (2010) (2)
- Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial). (2018) (2)
- TNFA induces elevated levels of nuclear TCF / beta catenin complexes in a colon carcinoma cell line (2000) (2)
- Outcome prediction to cetuximab in advanced colorectal cancer: Analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridization (2007) (2)
- Peripheral blood monocytes as biomarkers for colorectal cancer. (2013) (2)
- Fuzzy Multi-class Statistical Modeling for Efficient Total Lesion Metabolic Activity Estimation from Realistic PET Images (2012) (2)
- Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer (2013) (2)
- 3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00) (2007) (2)
- Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients treated in Europe. (2022) (2)
- Quantitative comparison of automated PET volume delineation methodologies using simulated tumor lesions (2011) (2)
- Current status of screening for colorectal cancer (2013) (2)
- Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer. (2009) (2)
- Abstract 940: Analytical and clinical validation of the Idylla™ ctKRAS and ctNRAS-BRAF liquid biopsy tests identifies mCRC patient groups with high and low ctDNA shedding (2018) (2)
- The role of the KRAS G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab. (2011) (2)
- Molecular defects in colorectal tumorigenesis. (2003) (1)
- Oncology and public health (2012) (1)
- AWARENESS AND UNDERSTANDING OF STRATIFIED/PERSONALIZED MEDICINE IN PATIENTS TREATED FOR CANCER: A MULTINATIONAL SURVEY (2012) (1)
- Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastroesophageal cancer in a large Belgian cohort. (2022) (1)
- Real-time diagnostic accuracy of blue light imaging, linked color imaging and white-light endoscopy for colorectal polyp characterization (2022) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- 457P Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations (2021) (1)
- ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours (2016) (1)
- adenomatous polyposis (FAP) Guidelines for the clinical management of familial (2008) (1)
- Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers. (2012) (1)
- A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy (2021) (1)
- Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia (2022) (1)
- Adjuvant chemotherapy for stage III colon cancer in 2005: where are we now? (2005) (1)
- DPYD Genotyping to Predict Adverse Events Following TreatmentWith Fluorouracil-Based Adjuvant Chemotherapy in PatientsWith Stage III Colon Cancer (2016) (1)
- DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial. (2015) (1)
- EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM). (2017) (1)
- 6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain (2011) (1)
- Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial) (2008) (1)
- PG 2.04 Systemic treatment of CRC: Molecular profiles ready for clinical practice? (2012) (1)
- 433 Identification of the BRAF-like Signature Predictive of Response Towards MEK Inhibition by Pimasertib (MSC1936369B) in Colorectal Cancer Cell Lines (2012) (1)
- IS9. colorectal cancer (2012) (1)
- Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition (2008) (1)
- Molecular classes in CRC: Characterization of MSI by expression profiling in the translational study of the PETACC 3-EORTC 40993- SAKK 60-00 trial. (2010) (1)
- A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. (2018) (1)
- Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements. (2017) (1)
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes (2013) (1)
- Abstract 579: Immune features and neoantigen recognition in mismatch repair-proficient colorectal cancer liver metastases (2019) (1)
- Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) (2023) (0)
- Semi-automated validation of centralized independent review of radiological data in the OPUS trial. (2014) (0)
- A lymph node-to-tumour PDL1+macrophage circuit antagonizes dendritic cell immunotherapy (2023) (0)
- 1 DNA topoisomerase I gene copy number and mRNA expression assessed as predictive biomarkers for adjuvant irinotecan in stage II/III colon cancer (2015) (0)
- Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation (2015) (0)
- Abstract 2795: Integrating multiomics discovery approaches to identify biomarkers of therapeutic resistance in metastatic colorectal cancer through analyses of multiple sequential tumor and liquid biopsies; Qcroc01: NCT00984048 (2017) (0)
- F1000Prime recommendation of Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. (2013) (0)
- Title: Cross-Species Analysis of Genetically Engineered Mouse Models of MAPK Driven (2014) (0)
- On using textural information from longitudinal PET scans for predicting tumor response (2012) (0)
- Pyk 2 and its phosphorylated form pY 881 are novel prognostic markers for non-small cell lung cancer progression and patients ' survival (2015) (0)
- Abstract 823: Colorectal cancer heterogeneity from a gene expression perspective. (2013) (0)
- Cancer Therapy : Preclinical Concomitant BRAFandPI 3 K / mTORBlockade IsRequired for Effective Treatment of BRAFV 600 E Colorectal Cancer (2013) (0)
- Genetic Biomarkers for Anti-angiogenic Therapies – a Race to Report (2010) (0)
- Abstract 479:BRAFandKRAS mutation define distinct subtypes of the CpG island methylator phenotype in colorectal cancers (2019) (0)
- Influence of intestinal flora on the development of adenomas in the APC1638N mouse (1999) (0)
- F1000Prime recommendation of Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. (2013) (0)
- Funding: Roche Disclosure: J. Bennouna: Advisory Board for Roche, Boehringer Ingelheim, (2017) (0)
- Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture (2022) (0)
- Optimizing Therapeutic Combinations of a Selective MEK 1/2 Inhibitor (Pimasertib) With PI3K/MTOR Inhibitors or With Multi-Targeted Kinase Inhibitors in Pimasertib-Resistant Human Lung and Colorectal Cancer Cells (2012) (0)
- Heterogeneity of EGFR and HER2 gene status by fluorescent in situ hybridization in colorectal cancer (2006) (0)
- RECURRENCE AFTER SURGERY FOR DUPUYTREN'S DISEASE: A RANDOMISED CONTROLLED TRIAL WITH DOUBLE BLINDING, COMBINING SEGMENTAL FASCIECTOMY WITH PLACEBO OR WITH NEO-ADJUV ANT ORAL TAMOXIFEN (2014) (0)
- Treated with Salvage Cetuximab / Panitumumab Monotherapy Improved Outcome in Patients with Metastatic Colorectal Cancer Predicts KRAS microRNA-Binding Site Polymorphism in let-7 A Updated (2014) (0)
- SP173 Predictive markers for EGFR targeting therapies (2009) (0)
- Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers. (2013) (0)
- Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer (2023) (0)
- Biopsies: next-generation biospecimens for tailoring therapy (vol 10, pg 437, 2013) (2013) (0)
- CRS+HIPC to treat peritoneal carcinomatosis from upper GI Cancer : 1-year analysis of the HIPCUPP-trial (2012) (0)
- Predictive Biomarkers and Personalized Medicine Hsa-miR-31-3 p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy (2014) (0)
- Transcriptional activation of Tcf/Lef in desmoids and colorectal cancer: Common molecular mechanisms leading to different tumor types (2000) (0)
- Mutations of the APC gene in FAP-associated and sporadic desmoid tumors. A common pathogenesis? (1999) (0)
- Familial Cancer Management (2006) (0)
- KRAS mutation analysis on low percentage of tumor cells: The importance of standardization and quality assurance (2011) (0)
- Panel discussion (CRC Summit) (2013) (0)
- Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era (2008) (0)
- Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer (2022) (0)
- Prognostication using molecular (mol) markers and clinicopathological (clpath) features in high-risk stage II/III colon cancer (CC). (2016) (0)
- Microsatellite instability versus microsatellite stability in colon carcinoma: documentation of tumour heterogeneity and inflammation (2015) (0)
- Levels of amphiregulin and epiregulin expression correlate with overall survival in colorectal cancer treated with cetuximab (2007) (0)
- Abstract 4162: PTPRO silencing by MAPK pathway in colorectal cancer (2012) (0)
- Personalizing treatment based on biomarkers (2010) (0)
- Prevention and management of cetuximab-related hypomagnesemia. (2022) (0)
- SYT and EWS abnormalities are recurrently occurring in poorly differentiated gastroesophageal cancers (2013) (0)
- BELGIAN ASSOCIATION FOR THE STUDY OF CANCER: (2004) (0)
- Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00) (2007) (0)
- Abstract LB-231: Genomic profiling in serial metastatic colorectal tumors identifies copy number alterations and spatio temporal intra-patient heterogeneity profiles associated with clinical response. Q-CROC-01: NCT00984048 (2018) (0)
- Abstract 3888: Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: (2015) (0)
- Abstract 1078: ErbB/Pi3K signaling contributes to EGFR ligand expression in colorectal cancer cells (2012) (0)
- Instability of EGFR gene status during progression of colorectal cancer (2007) (0)
- Faculty Opinions recommendation of Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. (2013) (0)
- EGFR and HER2 in colorectal cancer: Analysis of gene copy number and protein expression over disease progression. Does intratumoral heterogeneity matter? (2007) (0)
- Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy. (2019) (0)
- F1000Prime recommendation of Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. (2013) (0)
- Colon Cancer Adjuvant Treatment Trial Context: a Feasibility Study on the PETACC3 Stage II and III Tissue Biomarker Development in a Multicentre Trial (2009) (0)
- Colorectal cancer heterogeneity from a gene expressionperspective (2013) (0)
- Next-generation whole blood transcriptome-based assay for advanced adenoma detection. (2023) (0)
- POTENTIAL BIOMARKERS FOR RESPONSE TO CETUXIMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC). A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY (2012) (0)
- Ten Years of Mutation Analysis in Belgian HNPCC Patients (2009) (0)
- Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients. (2018) (0)
- RNF43 mutations facilitate colorectal cancer metastasis via formation of a tumour-intrinsic niche (2023) (0)
- Abstract 1218: PTPRO as a candidate phosphatase in regulating EGFR signaling in colorectal cancer (2012) (0)
- 188 RANBP2 knock-down is synthetic lethal with BRAF V600E in colon cancer (2014) (0)
- Gastrointestinal cancer—Science and clinical (2018) (0)
- Identification of colorectal cancer cells that mediate relapse after chemotherapy by marker gene Mex3a (2022) (0)
- The ZIC gene family encodes multi-functional proteins essential for patterning and morphogenesis (2013) (0)
- Accurate tumor lesion metabolic activity estimation (2012) (0)
- Mutation analysis in Belgian familial colorectal cancer kindreds: High proportion of novel mutations in the mismatch repair genes (2000) (0)
- Analysis of patients with a personal and/or family history of pancreatic cancer with a custom designed broad cancer predisposition gene panel (2019) (0)
- An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC). (2021) (0)
- 1111 POSTER The wide spectrum of cutaneous side effects of epidermal growth factor receptor inhibitors and their treatment: experience from a digestive oncology–dermatology collaboration (2007) (0)
- Evaluation of statistical distance metrics between longitudinal scans for predicting early tumor therapy response (2012) (0)
- Intrinsic Resistance To the Antiproliferative Effects of Azd6244 a Selective Mek1/2 Inhibitor Is Associated With Concomitant K-ras and Pi3kca Gene Mutations in Colorectal Cancer Cells (2010) (0)
- Session III. Improving Treatment of Pancreatic Cancer (2012) (0)
- Abstract 4281: Overcoming preanalytical variabilities for peripheral blood mononuclear cells and exosome profiling in the IMMUcan multicentre study (2020) (0)
- Publisher Correction: Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy (2022) (0)
- Connecting gene expression subtypes of colorectal cancer (CRC) with cell lines and drug resistance. (2013) (0)
- Genome-wide association study for germline prognostic markers in colorectal cancer. (2010) (0)
- How to overcome resistance to therapy? (2012) (0)
- Molecular portraits of colorectal cancer morphological regions (2023) (0)
- Publisher Correction: Zeb2 drives invasive and microbiota-dependent colon carcinoma (2020) (0)
- Abstract 4722: A BRAF-mutated gene expression signature identifies BRAF wild type colon cancer patients with poor prognosis (2011) (0)
- Safety and activity of ziv-aflibercept in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with colorectal cancer previously treated with irinotecan: Results from a phase 1 study. (2014) (0)
- SLAC: Statistical total lesion metabolic activity computation by fuzzy unsupervised learning of PET images (2012) (0)
- Pharmacogenomics of Colorectal Cancer Including Prognostic and Predictive Biomarkers (2010) (0)
- Upper gastrointestinal cancers: Are all carcinomas truly carcinomas? (2014) (0)
- Reply to C. Cremolini et al (2010) (0)
- Response prediction to EGFR-targeted therapies in colorectal cancer (2006) (0)
- Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in TranslationAL"? Reply (2010) (0)
- The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy. (2020) (0)
- Faculty Opinions recommendation of Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. (2013) (0)
- Abstract 1219: Identification of synthetic lethal interactions with the BRAF oncogene in colorectal cancer. (2013) (0)
- PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment (2019) (0)
- Bioinformatic / MS proteomic approach to identify a panel associated with the response to therapy in drug-resistant ovarian cancer tissue (2017) (0)
- 477P Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) (2021) (0)
- Implementation of Next-Generation-Sequencing in Oncology and Heamatology: a Belgian feasibility study (2015) (0)
- K-ras mutations and cetuximab in colorectal cancer. (2009) (0)
- Prediction of tumour response beyond ras (2010) (0)
- Faculty Opinions recommendation of Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial. (2013) (0)
- Abstract 6770: Spatial characterization of immune microenvironment from early onset metastatic colorectal cancer (EOmCRC) showed a dual prognostic role for IDO1 expression (2023) (0)
- Abstract A075: SPECTA: The EORTC translational research platform for Europe (2019) (0)
- Application of a custom designed broad cancer predisposition gene panel for the analysis of patients with a personal and/or family history of pancreatic cancer. (2019) (0)
- P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer (2021) (0)
- Predictive Biomarkers for Response to Cetuximab in Colorectal Cancer: KRAS Marches On (2008) (0)
- Identification of synthetic lethal interactions with the BRAF oncogene in colorectal cancer (2013) (0)
- SY-11-KL Challenges in identifying and applying molecular subgrouping in colorectal cancer (2013) (0)
- Screening for colorectal cancer. (1995) (0)
- Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells. (2013) (0)
- Bile acid composition in bile from APC mutant mice (1998) (0)
- Identification of germline mutations in cancer predisposition genes in patients with a personal and/or family history of pancreatic cancer (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sabine Tejpar?
Sabine Tejpar is affiliated with the following schools:
